ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

Outcomes, survival, and HRQOL in trials of new drugs (and what they mean in practice)

A new paper in the journal Quality of Life Research has raised the question of whether it is possible to use available quality of life data from Phase III trials of new drugs in the treatment of advanced prostate cancer to make rational decisions about the use of those drugs in clinical practice. … READ MORE …

Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Nuts to the Daily Telegraph … and nuts for most of our readers!

Finally, we may have the perfect paper that illustrates the critical difference between overall mortality rates and cancer-specific cancer rates among men with prostate cancer, and how affecting one may have no effect whatsoever on the other! … READ MORE …

Is overall survival a useful endpoint for evaluating therapies for intermediate-risk patients?

In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. … READ MORE …

Dose-escalated radiation therapy doesn’t impact survival within 10 years

Zaorsky et al. conducted a meta-analysis of 12 randomized clinical trials covering data on 6,884 patients treated with external beam radiation at various dose levels. … READ MORE …

Statin therapy lowers mortality rates among Danish prostate cancer patients

According to a media release and a presentation given at the European Association of Urology (EAU) in Europe this week, statin therapy has a small but significant impact on overall and prostate cancer-specific mortality rates. … READ MORE …